Mailand (688273, stock bar July 22 issued a prospectus, in which the subscription date of Mailand is August 2, 2022, Mailand's issue price of 40.29 yuan / share, the number of shares issued online is 6,375,000 shares. Nanjing Myland Medical Technology Co., Ltd. focuses on the research and development and industrialization of high-performance intelligent pelvic floor rehabilitation diagnostic and treatment system products, and provides high-level and all-round one-stop overall solutions for patients with pelvic floor dysfunction. It is a domestic enterprise providing pelvic floor rehabilitation diagnosis and treatment equipment products and solutions.
Is MAD worth buying?
Is MAD worth subscribing to? Looking at new stocks listed in the last month or so, the likelihood of earning a profit is reduced. stocks that broke the buck in late-July IPOs were concentrated in stocks with large issue sizes and high issue prices, so you need to be careful about subscribing.
[Purchase Information]
Stock Abbreviation
McLean's
Buy Code
787273
Stock Symbol
688273
Listed on the Stock Exchange
Shanghai Stock Exchange
Top of the line subscription requires market capitalization.
60,000 yuan
Number of online distribution
375,000 shares
Total number of issued shares
5 million shares
Offering price
40.29 yuan
Maider Purchase Date
August 2, 2022
Maider insists on taking the path of independent innovation and research and development of connotative development road, has passed ISO13485 medical device industry quality management system certification and ce product certification. Its products have obtained two national high-tech product certificates, one Nanjing biomedical new product certificate and one Nanjing innovative product. With the advantages of "complete product, excellent function and deep service", the products have been widely used in more than 8000 enterprises and institutions, won the praise of customers, and successfully established a number of pelvic floor rehabilitation demonstration bases.
In the future, Myland will continue to take "creating the ultimate health experience" as its mission, benchmarking against the international leading pelvic floor rehabilitation diagnostic system enterprises, and constantly consolidating its independent core competitiveness, in an effort to become a "world-class medical and healthcare company focusing on women's health and beauty! "
Company
The company's main departments include: Gynecology, Obstetrics and Gynecology, Obstetrics and Gynecology, Rehabilitation, Anal and Intestinal, Urology.
Market Position
The company has long adhered to the customer value as the core, market demand-oriented, technology innovation-driven, independent research and development and formed a series of products such as pelvic floor diagnostic and therapeutic equipment, postnatal recovery equipment, home equipment and supporting consumables, and has developed into an enterprise with a rich range of product models, a high level of intellectualization, a wide variety of application scenarios, and strong market competitiveness and influence. The entry threshold of pelvic floor and postpartum rehabilitation is high. At present, few domestic enterprises have obtained the registration certificate of pelvic floor diagnosis and treatment equipment. The company has established a dominant position in the industry by virtue of its technological research and development advantages and brand advantages. It has been recognized by the Ministry of Industry and Information Technology of the People's Republic of China (MIIT) as a 2018 Nanjing Gazelle Enterprise, a Potential Unicorn Enterprise in the South Jiangsu National Innovation Demonstration Zone, a Gazelle Enterprise in the South Jiangsu National Innovation Demonstration Zone, and a "Little Giant" Enterprise specializing in innovation.
Currently, the company has established a marketing network covering more than 1,000 dealers in 31 provinces, autonomous regions and municipalities directly under the central government. Statistical data from the 2019 Statistical Bulletin on the Development of China's Health Services show that in 2019, there were 2,749 tertiary hospitals (including 1,516 tertiary hospitals), 9,687 secondary hospitals, and 11,264 primary hospitals in the country***. Our products have been widely used in medical institutions at all levels, including more than 600 tertiary hospitals, more than 3,000 secondary hospitals and more than 1,000 primary hospitals. In addition, our products have been introduced into more than 3,000 professional institutions, including monthly child centers, maternal and child health centers, and postpartum recovery centers.
In 2019, 2020 and 2021, the company's revenue will be 25,566.65 million yuan, 33,651.97 million yuan and 34,164.25 million yuan, respectively, and its net profit will be 105,574.6 million yuan, 121,357.4 million yuan and 11,969.74 million yuan, respectively.
Looking at McLand's company profile, major product development, McLand's subscription information, here unfolds what is IPO subscription, subscription advice, best time to subscribe.
The purpose of IPO subscription is to get the very low risk spread income between the primary market and the secondary market, and not to participate in the secondary market speculation. Not only is the principal very safe, but the return is also relatively stable, making it an ideal investment choice for prudent investors. The IPO is the lowest risk, stable return investment in the stock market.IPO is the Initial Public Offering (IPO), which is the process by which a company issues shares to investors for the first time through the stock exchange in order to raise funds for the development of the company.
The IPO is suitable for investors with certain requirements for liquidity and risk tolerance, such as secondary market investors, bank financial investors and large enterprises and companies with idle funds.
Suggested purchases
1. Subscribing to new shares to pay money in advance rather than after winning. In this regard, industry insiders generally believe that the allocation of shares in accordance with the market value of shares held, and not prepaid, means that shareholders holding liquid market capitalization have the opportunity to subscribe to the new shares, but the winning rate will be lower.
2. The adjusted rule of non-payment after three winning bids adds the disciplinary measure of "investors who do not pay after three winning bids in 12 consecutive months will not be allowed to participate in new bids for six months".
Best time to buy new shares
Investors should pay attention to the time period when placing orders through the trading system of securities companies. The reason is that the new shares can only be placed once, you need to avoid the peak of the order, not only the probability of winning, but also a high rate of winning. After the study, investors commissioned the most intensive time period and the most successful time period is 10:30-11:30 am and 1:00-2:00 pm, the probability of winning is relatively high.
/u/cms/www/202208/01172858lb7b.jpg